Efficacy of an Eight Week Trial of Imipramine and Citalopram in Patients with Mixed Anxiety-Depressive Disorder
Objective: Mixed anxiety-depressive disorder (MADD) is a condition in which patients have both anxiety and depressive symptoms but do not meet the diagnostic criteria for either an anxiety disorder or a mood disorder. The aim of this study was to compare the efficacy of imipramine and citalopram in...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2008-12-01
|
| Series: | Iranian Journal of Psychiatry |
| Subjects: | |
| Online Access: | https://ijps.tums.ac.ir/index.php/ijps/article/view/487 |
| _version_ | 1819044589603913728 |
|---|---|
| author | Mohammad Reza Abbasi-Asl Abbas Alimadadi Hasan Khoonsari Hossein Khalili Padideh Ghaeli Mohammad Sanatti Mahdiyeh Moin Mansoor Rastegarpanah Ghaeli Pharm |
| author_facet | Mohammad Reza Abbasi-Asl Abbas Alimadadi Hasan Khoonsari Hossein Khalili Padideh Ghaeli Mohammad Sanatti Mahdiyeh Moin Mansoor Rastegarpanah Ghaeli Pharm |
| author_sort | Mohammad Reza Abbasi-Asl |
| collection | DOAJ |
| description | Objective: Mixed anxiety-depressive disorder (MADD) is a condition in which patients have both anxiety and depressive symptoms but do not meet the diagnostic criteria for either an anxiety disorder or a mood disorder. The aim of this study was to compare the efficacy of imipramine and citalopram in the treatment of MADD.
Methods: Fifty one outpatients aged 18 to 55 who were diagnosed with MADD were randomly assigned to receive citalopram or imipramine for 8 weeks. Patients were assessed using Hamilton Depression Rating Scale (HDRS) and Hamilton Anxiety Rating Scale (HARS) at baseline, weeks 4 and 8 of the study. The mean differences in Hamilton scores from the baseline were used as the main outcome measures of response to treatment.
Results: Thirty six patients completed the study. Patients in the citalopramgroup (n=20) received a mean dosage of 22 mg per day during the first 4 weeks and a mean dosage of 33 mg per day during weeks 4 to 8. Subjects in the Imipramine group (n= 16) received a mean dosage of 77 mg per day during the first 4 weeks and a mean dosage of 89 mg per day during weeks 4 to 8. It was noted that the both treatments were effective on depression andanxiety at the end of the fourth and eighth weeks. However, the mean differences of HDRS and HARS scores between citalopram and imipraminegroups were not significantly different at the end of weeks 4 and 8.
Conclusion: The results of this study suggest that the efficacy of regular doses of citalopram is comparable with lower range of therapeutic doses of imipramine in the treatment of MADD. A more comprehensive study is warranted to confirm the results of this study. |
| first_indexed | 2024-12-21T10:15:05Z |
| format | Article |
| id | doaj.art-575d5ba3edbe451f98cdcd2f8514dc47 |
| institution | Directory Open Access Journal |
| issn | 1735-4587 2008-2215 |
| language | English |
| last_indexed | 2024-12-21T10:15:05Z |
| publishDate | 2008-12-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Iranian Journal of Psychiatry |
| spelling | doaj.art-575d5ba3edbe451f98cdcd2f8514dc472022-12-21T19:07:37ZengTehran University of Medical SciencesIranian Journal of Psychiatry1735-45872008-22152008-12-0134Efficacy of an Eight Week Trial of Imipramine and Citalopram in Patients with Mixed Anxiety-Depressive DisorderMohammad Reza Abbasi-Asl0Abbas Alimadadi1Hasan Khoonsari2Hossein Khalili3Padideh Ghaeli4Mohammad Sanatti5Mahdiyeh Moin6Mansoor Rastegarpanah7Ghaeli Pharm8Department of psychiatry, Tehran University, of Medical Sciences, Tehran, IranUniversity of Applied Science and Technology, Tehran, IranFaculty of Pharmacy, Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, IranFaculty of Pharmacy, Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, IranDepartment of psychiatry, Tehran University, of Medical Sciences, Tehran, IranDepartment of psychiatry, Tehran University, of Medical Sciences, Tehran, IranDepartment of psychiatry, Tehran University, of Medical Sciences, Tehran, IranFaculty of Pharmacy, Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, IranPsychiatry & Psychology Research Center, Tehran University of Medical Sciences, Tehran, Iran Faculty of Pharmacy, Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, IranObjective: Mixed anxiety-depressive disorder (MADD) is a condition in which patients have both anxiety and depressive symptoms but do not meet the diagnostic criteria for either an anxiety disorder or a mood disorder. The aim of this study was to compare the efficacy of imipramine and citalopram in the treatment of MADD. Methods: Fifty one outpatients aged 18 to 55 who were diagnosed with MADD were randomly assigned to receive citalopram or imipramine for 8 weeks. Patients were assessed using Hamilton Depression Rating Scale (HDRS) and Hamilton Anxiety Rating Scale (HARS) at baseline, weeks 4 and 8 of the study. The mean differences in Hamilton scores from the baseline were used as the main outcome measures of response to treatment. Results: Thirty six patients completed the study. Patients in the citalopramgroup (n=20) received a mean dosage of 22 mg per day during the first 4 weeks and a mean dosage of 33 mg per day during weeks 4 to 8. Subjects in the Imipramine group (n= 16) received a mean dosage of 77 mg per day during the first 4 weeks and a mean dosage of 89 mg per day during weeks 4 to 8. It was noted that the both treatments were effective on depression andanxiety at the end of the fourth and eighth weeks. However, the mean differences of HDRS and HARS scores between citalopram and imipraminegroups were not significantly different at the end of weeks 4 and 8. Conclusion: The results of this study suggest that the efficacy of regular doses of citalopram is comparable with lower range of therapeutic doses of imipramine in the treatment of MADD. A more comprehensive study is warranted to confirm the results of this study.https://ijps.tums.ac.ir/index.php/ijps/article/view/487Anxiety disorderCitalopramDepressive disoderImipramine |
| spellingShingle | Mohammad Reza Abbasi-Asl Abbas Alimadadi Hasan Khoonsari Hossein Khalili Padideh Ghaeli Mohammad Sanatti Mahdiyeh Moin Mansoor Rastegarpanah Ghaeli Pharm Efficacy of an Eight Week Trial of Imipramine and Citalopram in Patients with Mixed Anxiety-Depressive Disorder Iranian Journal of Psychiatry Anxiety disorder Citalopram Depressive disoder Imipramine |
| title | Efficacy of an Eight Week Trial of Imipramine and Citalopram in Patients with Mixed Anxiety-Depressive Disorder |
| title_full | Efficacy of an Eight Week Trial of Imipramine and Citalopram in Patients with Mixed Anxiety-Depressive Disorder |
| title_fullStr | Efficacy of an Eight Week Trial of Imipramine and Citalopram in Patients with Mixed Anxiety-Depressive Disorder |
| title_full_unstemmed | Efficacy of an Eight Week Trial of Imipramine and Citalopram in Patients with Mixed Anxiety-Depressive Disorder |
| title_short | Efficacy of an Eight Week Trial of Imipramine and Citalopram in Patients with Mixed Anxiety-Depressive Disorder |
| title_sort | efficacy of an eight week trial of imipramine and citalopram in patients with mixed anxiety depressive disorder |
| topic | Anxiety disorder Citalopram Depressive disoder Imipramine |
| url | https://ijps.tums.ac.ir/index.php/ijps/article/view/487 |
| work_keys_str_mv | AT mohammadrezaabbasiasl efficacyofaneightweektrialofimipramineandcitalopraminpatientswithmixedanxietydepressivedisorder AT abbasalimadadi efficacyofaneightweektrialofimipramineandcitalopraminpatientswithmixedanxietydepressivedisorder AT hasankhoonsari efficacyofaneightweektrialofimipramineandcitalopraminpatientswithmixedanxietydepressivedisorder AT hosseinkhalili efficacyofaneightweektrialofimipramineandcitalopraminpatientswithmixedanxietydepressivedisorder AT padidehghaeli efficacyofaneightweektrialofimipramineandcitalopraminpatientswithmixedanxietydepressivedisorder AT mohammadsanatti efficacyofaneightweektrialofimipramineandcitalopraminpatientswithmixedanxietydepressivedisorder AT mahdiyehmoin efficacyofaneightweektrialofimipramineandcitalopraminpatientswithmixedanxietydepressivedisorder AT mansoorrastegarpanah efficacyofaneightweektrialofimipramineandcitalopraminpatientswithmixedanxietydepressivedisorder AT ghaelipharm efficacyofaneightweektrialofimipramineandcitalopraminpatientswithmixedanxietydepressivedisorder |